GSK (GSK) Earnings Date & Reports

Key Takeaways

• GSK plc is scheduled to report its third quarter 2026 results on Wednesday, 28 October 2026, before the market opens.
• Consensus estimates point to third-quarter revenue of roughly £8.89 billion, up about 4% year over year.
• Core earnings per share (EPS, profit attributable to each ordinary share excluding certain one-off items) are expected to come in near 50.8p, broadly in line with last year's comparable period.
• Analysts expect strength in HIV medicines and the respiratory drug Nucala to partly offset softer vaccine sales, particularly Shingrix.
• Investors are watching whether management narrows its full-year 2026 guidance and how it frames recent pipeline and regulatory catalysts.

Earnings Context and Why It Matters

GSK's third quarter update carries outsized weight because it lands at a pivotal moment for the pharmaceutical giant's growth narrative. The company has delivered a steady start to 2026, with strong Specialty Medicines momentum and improving core operating margins, even as parts of its vaccine franchise face pricing pressure. This report will test whether that balanced mix can continue. It also arrives alongside two significant near-term catalysts: a U.S. regulatory decision on the hepatitis B treatment bepirovirsen and an oncology investor update. For investors, the quarter offers a read on demand trends, margin discipline, and whether management is confident enough to tighten its full-year outlook.

Earnings Expectations

Ahead of the 28 October release, the Wall Street consensus calls for third-quarter revenue of about £8.89 billion, which would represent growth of roughly 4% compared with £8.55 billion a year earlier. Core EPS is expected to land near 50.8p, essentially matching the prior-year period, according to broker estimates compiled from company filings and analyst research.

Within the mix, RBC Capital Markets projects a broadly in-line quarter, forecasting revenue of £8.82 billion and core EPS of 50.8p. The broker sees vaccines as the main drag, with Shingrix sales of about £800 million versus a £837 million consensus, citing pricing pressure and high channel inventories in China. HIV medicines should provide a partial offset, led by the injectable treatment Cabenuva, while Nucala is expected to outperform after its expansion into chronic obstructive pulmonary disease (COPD, a progressive lung condition).

For context, GSK reported second-quarter 2026 sales of £8.41 billion, up 5%, with core EPS of 50.5p, up 9%. The company's full-year 2026 guidance calls for turnover growth of 3% to 5% and core operating profit and core EPS growth of 7% to 9%, all at constant exchange rates (CER, which strips out currency movements).

AI Screener

For investors looking to cut through the noise around earnings season, Tickeron's AI Screener offers a data-driven way to filter the market. The tool is an AI-powered stock and ETF discovery platform that helps traders and investors scan thousands of securities based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can apply customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. Whether you are hunting for trade ideas, trending stocks, breakout candidates, or broader market opportunities, the AI Screener can streamline the process far more efficiently than manual screening.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious but constructive. GSK shares have been supported by the company's recent track record of exceeding consensus estimates, with the stock historically responsive to surprises in core EPS and pipeline commentary. However, vaccine pricing headwinds and a softer international outlook for Dovato have tempered enthusiasm. Analysts at RBC maintain a neutral "Sector Perform" rating, suggesting expectations for a modest, uneventful print rather than a dramatic beat. Key risks include any sharper-than-expected decline in Shingrix revenue, unfavorable currency movements, or guidance language that signals rising costs tied to the Nuvalent acquisition and increased investment in research and development.

Forward Outlook and Key Factors to Monitor

Looking beyond the third quarter, investors should focus on several themes. First is guidance. RBC expects GSK to narrow its full-year 2026 outlook toward revenue growth of 4% to 5% and core earnings growth of 7% to 8%, a move that would signal confidence in the business trajectory. Any adjustment to core EPS expectations will be scrutinized closely, particularly given the additional interest costs associated with the Nuvalent acquisition.

Second, watch the vaccine franchise. Shingrix remains a bellwether for the segment, and sustained pricing pressure or inventory challenges in key markets such as China could weigh on sentiment even if other parts of the business perform well.

Third, the pipeline and regulatory calendar matter. A U.S. decision on bepirovirsen for hepatitis B and an oncology update arrive within days of the earnings release, giving management an opportunity to frame its late-stage growth story. Finally, keep an eye on cost discipline and margin trends, as rising R&D investment and deal-related financing costs will shape how efficiently top-line growth translates into profit.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations